Flexion Therapeutics Inc: management transactions · United States · SEC (Form 4)

About Flexion Therapeutics Inc

Flexion Therapeutics Inc. was a U.S.-based biopharmaceutical company focused on musculoskeletal pain, especially osteoarthritis, and it was listed in the U.S. on a major exchange market (NASDAQ/NYSE context). Headquartered in Burlington, Massachusetts, United States, the company built its strategy around local therapies designed to deliver medication directly to the site of pain, with the goal of improving efficacy while reducing systemic exposure. That positioning gave Flexion a clear identity in the non-opioid pain-management segment, where innovation in drug delivery could matter as much as the active ingredient itself. Flexion’s core commercial asset was ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide for osteoarthritis knee pain. ZILRETTA received FDA approval in 2017 and became the company’s flagship product. Its differentiation came from proprietary microsphere technology intended to provide longer-lasting relief than conventional steroid injections. In investor and company communications, Flexion also discussed a broader research pipeline for musculoskeletal conditions and additional local therapies, but in practice the company remained largely a single-product story before the corporate transaction that ended its independence. From a competitive standpoint, Flexion operated in a large but crowded market spanning orthopedics, pain management, and alternatives to opioid-based treatment. Its key competitive advantages were the novel formulation of ZILRETTA, its focused clinical positioning in knee osteoarthritis, and the potential to address a common condition with an extended-release, intra-articular therapy. The company’s commercial footprint was primarily domestic, with operations and commercialization centered in the United States rather than a globally diversified business model. The most important recent development is that Flexion is no longer an independent public company. Pacira BioSciences completed its acquisition of Flexion on November 19, 2021, and ZILRETTA was folded into Pacira’s broader non-opioid pain portfolio. For investors analyzing Form 4 insider transactions under the FLXN ticker, this matters materially: the name is now mainly relevant in a historical, corporate-action, or legacy SEC filing context rather than as an active standalone equity story.